The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnose...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a3554c9245464d81943eb2087b792037 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a3554c9245464d81943eb2087b792037 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a3554c9245464d81943eb2087b7920372021-11-05T09:13:15ZThe Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review1663-981210.3389/fphar.2021.751214https://doaj.org/article/a3554c9245464d81943eb2087b7920372021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.751214/fullhttps://doaj.org/toc/1663-9812Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnosed with or at high risk of atherosclerotic cardiovascular disease (ASCVD). In this mini review, we examine the role of SGLT2-is in the development and progression of atherosclerosis throughout its spectrum, from subclinical atherosclerosis to ASCVD.Data Sources—PubMed and Google Scholar were searched for publications related to SGLT2-is and atherosclerosis. All types of articles were considered, including clinical trials, animal studies, in vitro observations, and reviews and meta-analyses. Data were examined according to their impact and clinical relevance.Synopsis of Content—We first review the underlying mechanisms of SGLT2-is on the development and progression of atherosclerosis, including favorable effects on lipid metabolism, reduction of systemic inflammation, and improvement of endothelial function. We then discuss the putative impact of SGLT2-is on the formation, composition, and stability of atherosclerotic plaque. Furthermore, we evaluate the effects of SGLT2-is in subclinical atherosclerosis assessed by carotid intima media thickness and pulse wave velocity. Subsequently, we summarize the effects of SGLT2-is in ASCVD events, including ischemic stroke, angina pectoris, myocardial infarction, revascularization, and peripheral artery disease, as well as major adverse cardiovascular events, cardiovascular mortality, heart failure, and chronic kidney disease. Moreover, we examine factors that could modify the role of SGLT2-is in atherosclerosis, including sex, age, diabetes, glycemic control, ASCVD, and SGLT2-i compounds. Additionally, we propose future directions that can improve our understanding of SGLT2-is and atherosclerosis.Aurélie Pahud de MortangesDante Salvador Jr.Dante Salvador Jr.Markus LaimerTaulant MukaMatthias WilhelmArjola BanoArjola BanoFrontiers Media S.A.articleatherosclerotic cardiovascular diseaseSGLT2-inhibitorssubclinical atherosclerosisdiabetesreviewTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
atherosclerotic cardiovascular disease SGLT2-inhibitors subclinical atherosclerosis diabetes review Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
atherosclerotic cardiovascular disease SGLT2-inhibitors subclinical atherosclerosis diabetes review Therapeutics. Pharmacology RM1-950 Aurélie Pahud de Mortanges Dante Salvador Jr. Dante Salvador Jr. Markus Laimer Taulant Muka Matthias Wilhelm Arjola Bano Arjola Bano The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| description |
Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnosed with or at high risk of atherosclerotic cardiovascular disease (ASCVD). In this mini review, we examine the role of SGLT2-is in the development and progression of atherosclerosis throughout its spectrum, from subclinical atherosclerosis to ASCVD.Data Sources—PubMed and Google Scholar were searched for publications related to SGLT2-is and atherosclerosis. All types of articles were considered, including clinical trials, animal studies, in vitro observations, and reviews and meta-analyses. Data were examined according to their impact and clinical relevance.Synopsis of Content—We first review the underlying mechanisms of SGLT2-is on the development and progression of atherosclerosis, including favorable effects on lipid metabolism, reduction of systemic inflammation, and improvement of endothelial function. We then discuss the putative impact of SGLT2-is on the formation, composition, and stability of atherosclerotic plaque. Furthermore, we evaluate the effects of SGLT2-is in subclinical atherosclerosis assessed by carotid intima media thickness and pulse wave velocity. Subsequently, we summarize the effects of SGLT2-is in ASCVD events, including ischemic stroke, angina pectoris, myocardial infarction, revascularization, and peripheral artery disease, as well as major adverse cardiovascular events, cardiovascular mortality, heart failure, and chronic kidney disease. Moreover, we examine factors that could modify the role of SGLT2-is in atherosclerosis, including sex, age, diabetes, glycemic control, ASCVD, and SGLT2-i compounds. Additionally, we propose future directions that can improve our understanding of SGLT2-is and atherosclerosis. |
| format |
article |
| author |
Aurélie Pahud de Mortanges Dante Salvador Jr. Dante Salvador Jr. Markus Laimer Taulant Muka Matthias Wilhelm Arjola Bano Arjola Bano |
| author_facet |
Aurélie Pahud de Mortanges Dante Salvador Jr. Dante Salvador Jr. Markus Laimer Taulant Muka Matthias Wilhelm Arjola Bano Arjola Bano |
| author_sort |
Aurélie Pahud de Mortanges |
| title |
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| title_short |
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| title_full |
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| title_fullStr |
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| title_full_unstemmed |
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review |
| title_sort |
role of sglt2 inhibitors in atherosclerosis: a narrative mini-review |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/a3554c9245464d81943eb2087b792037 |
| work_keys_str_mv |
AT aureliepahuddemortanges theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT dantesalvadorjr theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT dantesalvadorjr theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT markuslaimer theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT taulantmuka theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT matthiaswilhelm theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT arjolabano theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT arjolabano theroleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT aureliepahuddemortanges roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT dantesalvadorjr roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT dantesalvadorjr roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT markuslaimer roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT taulantmuka roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT matthiaswilhelm roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT arjolabano roleofsglt2inhibitorsinatherosclerosisanarrativeminireview AT arjolabano roleofsglt2inhibitorsinatherosclerosisanarrativeminireview |
| _version_ |
1718444427606753280 |